Ridge Bio

• 10/09/2025
• Seed
• $25,000,000

Ridge Biotechnologies is pioneering AI-based enzyme and targeted drug design to power the next wave of precision therapeutics.

Led by a collection of established biotech entrepreneurs and faculty from top institutions, we use proprietary machine learning models informed by high-throughput cell-free experimentation for a wide range of applications in antibody-drug conjugates (ADCs), conditionally active prodrugs, in vivo CART therapies, targeted nucleic acid delivery, radiotherapies, and enzyme-based therapeutics.

Our current product lines include NativeLink enzymes that enable precision bioconjugation including construction of ADCs and Antibody-oligonucleotide conjugates, ProTrigger linkers that provide tissue and disease-specific activation and release of diverse payloads and prodrugs, and new classes of enzyme-based Catalytic Medicines.

We are focused on enabling our partners to build better drugs for patients.

---

---